###begin article-title 0
Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris
###end article-title 0
###begin p 1
###xml 974 975 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 949 957 <span type="species:ncbi:9606">patients</span>
###xml 1207 1215 <span type="species:ncbi:9606">patients</span>
Serotonin is a monoamine acting as a neuromediator in the central and peripheral nervous system. Recently, serotonin has also been shown to influence T- and B-cell function. The serotonin transporter is central in the regulation of the serotonergic system and widely expressed on cells of the immune system. A functional length polymorphism in the promoter of the serotonin transporter gene (5-HTTLPR) has been implicated in the genetic background of depression. Psoriasis is a complex disease with a polygenetic inheritance. In light of the role of T-cell mediated inflammation in psoriasis and the increased prevalence of depression in psoriatic patients, we analyzed the 5-HTTLPR polymorphism in 309 patients with psoriasis vulgaris and 315 healthy control individuals. No significant differences in genotype distribution and allele frequencies were found. There was also no difference in the score of the Hamilton Rating Scale for Depression in patients with psoriasis (n = 137) characterized by carriage of different 5-HTTLPR genotypes. These findings argue against a major contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility and the occurrence of depressive symptoms among psoriatic patients.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 449 450 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 706 707 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 662 670 <span type="species:ncbi:9606">patients</span>
###xml 1151 1159 <span type="species:ncbi:9606">patients</span>
Psoriasis vulgaris is a complex disease with multifactorial inheritance affecting approximately 2-3% of the population. It is believed that cells of the innate and acquired immune system, among them dendritic cells and T-cells, collaborate to produce a pattern of cutaneous angiogenesis, inflammation and epidermal changes that underlie the formation of sharply demarcated erythematosquamous plaques, the typical clinical presentation of psoriasis [3]. Because psoriasis is a chronic, often widespread and stigmatizing condition that may extensively reduce the quality of life of affected patients, the observed increased prevalence of depressive symptoms among patients compared with healthy individuals [1] can possibly be regarded as secondary to the manifestation of a significant medical condition. It is also not excluded that the psoriatic inflammatory process plays a direct role via the constantly increased production of mediators that may also influence mental functions or that psoriasis and depression share common risk factors at the genetic level. On the other hand, it has been suggested that stress can aggravate skin inflammation in patients with psoriasis, indicating another level of possible interactions between psychological symptoms and skin inflammation.
###end p 4
###begin p 5
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 974 975 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1036 1037 1036 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
The serotonergic system is a promising candidate for establishing a neuroimmunological link between psoriatic skin disease and psychological symptoms. In the central nervous system, serotonergic neurons project to almost all regions of the brain and influence many physiological functions such as pain, sleep, motor functions, neuroendocrine circuits and the mood. The main producers of 5-HT are enterochromaffin cells of the gut and the serotonergic neurons of the brain, but 5-HT is stored in many cell types outside the central nervous system including platelets, lymphocytes, monocytes/macrophages and dendritic cells [6]. Recently, it has been shown that lymphocytes also synthesize and excrete 5-HT [17]. The production of 5-HT is increased at sites of inflammation and several functional activities of 5-HT have been revealed that play an important role in chronic inflammatory diseases such as psoriasis including the activation of mast cell migration and adhesion [9], the stimulation of cytokine release from dendritic cells [8] and the mediation of dendritic cell-T-cell interactions [17].
###end p 5
###begin p 6
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
The expression and function of the serotonin transporter (5-HTT), which is responsible for the uptake of 5-HT into cells thereby removing 5-HT from the extracellular space, is a key parameter in the regulation of 5-HT-mediated effects in the central nervous system and the immune system [15]. The expression of 5-HTT is controlled by a repeat length polymorphism in the 5-HTT linked polymorphic region (5-HTTLPR). The long (high activity) allele of this polymorphism is associated with a higher number of 5-HTT molecules on lymphocytes [10]. The biological relevance of the 5-HTTLPR polymorphism is underscored by the recent finding of an association with primary pulmonary hypertension [5], and the observed influence on the development of depressive symptoms in individuals afflicted by a negative life event as well as on suicidal behavior [11].
###end p 6
###begin p 7
###xml 184 192 <span type="species:ncbi:9606">patients</span>
In this study, we used a case-control design to obtain first evidence whether the 5-HTTLPR polymorphism is associated with psoriasis. We also compared depressive symptoms in psoriatic patients characterized by carriage of different 5-HTTLPR genotypes.
###end p 7
###begin title 8
Subjects and methods
###end title 8
###begin title 9
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 9
###begin p 10
###xml 668 670 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Unrelated German Caucasian patients with an established diagnosis of chronic plaque-type psoriasis were enrolled from the Department of Dermatology, University Hospital Gottingen (309 individuals, 127 female, 182 male, age 46.0 +/- 14.3 years (mean +/- SD), positive family history in 140 cases). The control group consisted of healthy unrelated German Caucasians without a personal or family history of psoriasis (315 individuals, 146 female, 169 male, age 35.6 +/- 12.1 years (mean +/- SD)) recruited from the blood donor registry of the Department of Transfusion Medicine, University Hospital Gottingen and from local health-care personnel as described previously [20].
###end p 10
###begin p 11
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
To assess the presence of depressive symptoms, the Hamilton Rating Scale for Depression (HAM-D) was performed in the subgroup of 137 patients of patients aged between 18 and 60 years who were recruited between May 2004 and November 2005. The HAM-D is a validated scale that is routinely used for the assessment of depression and rates the severity of 21 symptoms typical of depression, from which a sum score is calculated. The HAM-D can take on values between 0 and 67, and the score of >8, >14 and >19 is considered to reflect a mild, moderate and severe depression, respectively.
###end p 11
###begin p 12
###xml 155 167 <span type="species:ncbi:9606">participants</span>
The study was approved by the Institutional Review Board of the Medical Faculty of the University of Gottingen, and informed consent was obtained from all participants.
###end p 12
###begin title 13
Genotyping of the 5-HTT promoter polymorphism (5-HTTLPR)
###end title 13
###begin p 14
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
Genomic DNA was prepared from peripheral blood mononuclear cells according to the published protocols [13].
###end p 14
###begin p 15
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCL6A4</italic>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 513 516 511 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
The 5-HTT linked polymorphic region (5-HTTLPR) of the gene encoding SERT (SCL6A4) located on chromosome 17q11.1-12 was amplified by the flanking oligonucleotide primers 5'-GAG GGA CTG AGC TGG ACA AC-3' and 5'-GCA GCA GAC AAC TGT GTT CAT C-3'. The short (s) allele is 44 bp shorter than the long (l) allele due to a 44 bp deletion [7]. PCR was performed in a final solution of 20 mul containing between 200 and 600 ng genomic DNA, 0.2 mM dNTP, 0.2 mM deaza-GTP, 0.5 muM of each primer, 2% dimethylsulfoxide, 2.5 U Taq polymerase in PCR buffer (Promega).
###end p 15
###begin p 16
After an initial denaturation for 3 min at 95degreesC, 43 cycles of denaturing at 95degreesC for 30 s, annealing for 30 s and extension at 72degreesC for 1 min were performed, followed by a final extension at 72degreesC for 10 min. Annealing was performed at 65degreesC for the first four cycles, 64degreesC for the subsequent four cycles and 63degreesC during the final 35 cycles.
###end p 16
###begin p 17
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 168 174 168 174 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 225 226 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 254 256 254 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ls</italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 319 321 319 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ls</italic>
###xml 323 327 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane</italic>
###xml 340 342 340 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ss</italic>
###xml 372 374 372 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ll</italic>
###xml 174 374 174 374 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18">Example for genotyping of 5-HTTLPR in 18 probands. <italic>+</italic> Positive control (genotype <italic>ls</italic>), &#8722; negative control, <italic>lanes</italic> P1, P2, P6, P8, P13, P17 genotype <italic>ls</italic>, <italic>lane</italic> P9 genotype <italic>ss</italic>, remaining probands genotype <italic>ll</italic></p>
###xml 174 374 174 374 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18">Example for genotyping of 5-HTTLPR in 18 probands. <italic>+</italic> Positive control (genotype <italic>ls</italic>), &#8722; negative control, <italic>lanes</italic> P1, P2, P6, P8, P13, P17 genotype <italic>ls</italic>, <italic>lane</italic> P9 genotype <italic>ss</italic>, remaining probands genotype <italic>ll</italic></p></caption>
###xml 374 374 374 374 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="403_2008_909_Fig1_HTML" id="MO1"/>
###xml 168 374 168 374 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="18">Example for genotyping of 5-HTTLPR in 18 probands. <italic>+</italic> Positive control (genotype <italic>ls</italic>), &#8722; negative control, <italic>lanes</italic> P1, P2, P6, P8, P13, P17 genotype <italic>ls</italic>, <italic>lane</italic> P9 genotype <italic>ss</italic>, remaining probands genotype <italic>ll</italic></p></caption><graphic position="anchor" xlink:href="403_2008_909_Fig1_HTML" id="MO1"/></fig>
PCR products were visualized on an agarose gel containing ethidium bromide. The variants were detected according to their size relative to a 100 bp DNA ladder (Fig. 1).Fig. 1Example for genotyping of 5-HTTLPR in 18 probands. + Positive control (genotype ls), - negative control, lanes P1, P2, P6, P8, P13, P17 genotype ls, lane P9 genotype ss, remaining probands genotype ll
###end p 17
###begin p 18
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 80 82 80 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ls</italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 145 147 145 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ls</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane</italic>
###xml 166 168 166 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ss</italic>
###xml 198 200 198 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ll</italic>
Example for genotyping of 5-HTTLPR in 18 probands. + Positive control (genotype ls), - negative control, lanes P1, P2, P6, P8, P13, P17 genotype ls, lane P9 genotype ss, remaining probands genotype ll
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 174 176 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 493 494 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 543 544 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
To determine whether the genotype frequencies confirmed with Hardy-Weinberg equilibrium, the equivalence test proposed by Wellek was used (5% test level) with epsilon = 0.1 [24]. Odds ratios (ORs) and exact 95% confidence intervals (CIs) were calculated to compare the genotype frequencies. Differences in genotype frequencies were investigated using an exact Cochrane-Armitage trend test. Differences in the HAM-D among different genotypes were compared using the non-parametric Mann-Whitney U test. The overall significance level was set to p = 0.05.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 470 477 468 475 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 477 507 475 505 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">5-HTTLPR genotype distribution</p>
###xml 477 507 475 505 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">5-HTTLPR genotype distribution</p></caption>
###xml 507 507 505 505 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 507 525 505 523 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Psoriasis patients</th>
###xml 525 538 523 536 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control group</th>
###xml 538 538 536 536 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 538 538 536 536 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 507 538 505 536 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2"/><th align="left">Psoriasis patients</th><th align="left">Control group</th><th align="left" rowspan="2"/><th align="left" rowspan="2"/></tr>
###xml 538 539 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 538 545 536 543 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic>&#160;=&#160;309</th>
###xml 545 546 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 545 552 543 550 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic>&#160;=&#160;315</th>
###xml 538 552 536 550 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>n</italic>&#160;=&#160;309</th><th align="left"><italic>n</italic>&#160;=&#160;315</th></tr>
###xml 507 552 505 550 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2"/><th align="left">Psoriasis patients</th><th align="left">Control group</th><th align="left" rowspan="2"/><th align="left" rowspan="2"/></tr><tr><th align="left"><italic>n</italic>&#160;=&#160;309</th><th align="left"><italic>n</italic>&#160;=&#160;315</th></tr></thead>
###xml 552 560 550 558 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Genotype</td>
###xml 560 561 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 560 565 558 563 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic> (%)</td>
###xml 565 566 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 565 570 563 568 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic> (%)</td>
###xml 570 572 568 570 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">OR</td>
###xml 572 573 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 573 574 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 573 574 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
###xml 572 574 570 572 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic><sup><italic>a</italic></sup></td>
###xml 552 574 550 572 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left">OR</td><td align="left"><italic>p</italic><sup><italic>a</italic></sup></td></tr>
###xml 574 576 572 574 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ll</td>
###xml 576 586 574 584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">104 (33.7)</td>
###xml 586 596 584 594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">108 (34.3)</td>
###xml 596 596 594 594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 596 596 594 594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 574 596 572 594 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ll</td><td align="left">104 (33.7)</td><td align="left">108 (34.3)</td><td align="left"/><td align="left"/></tr>
###xml 596 598 594 596 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ls</td>
###xml 598 608 596 606 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">144 (46.6)</td>
###xml 608 618 606 616 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">155 (49.2)</td>
###xml 618 634 616 632 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.08 (0.86&#8211;1.36)</td>
###xml 634 634 632 632 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 596 634 594 632 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ls</td><td align="left">144 (46.6)</td><td align="left">155 (49.2)</td><td align="left">1.08 (0.86&#8211;1.36)</td><td align="left"/></tr>
###xml 634 636 632 634 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ss</td>
###xml 636 645 634 643 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">61 (19.7)</td>
###xml 645 654 643 652 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">52 (16.5)</td>
###xml 654 670 652 668 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.17 (0.74&#8211;1.85)</td>
###xml 670 675 668 673 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.496</td>
###xml 634 675 632 673 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ss</td><td align="left">61 (19.7)</td><td align="left">52 (16.5)</td><td align="left">1.17 (0.74&#8211;1.85)</td><td align="left">0.496</td></tr>
###xml 675 675 673 673 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 692 693 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 675 693 673 691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Type 1 psoriasis <sup>b</sup></td>
###xml 710 711 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 693 711 691 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Type 2 psoriasis <sup>c</sup></td>
###xml 711 711 709 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 711 711 709 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 675 711 673 709 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2"/><td align="left">Type 1 psoriasis <sup>b</sup></td><td align="left">Type 2 psoriasis <sup>c</sup></td><td align="left" rowspan="2"/><td align="left" rowspan="2"/></tr>
###xml 711 712 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 711 718 709 716 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic>&#160;=&#160;224</td>
###xml 718 719 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 718 724 716 722 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic>&#160;=&#160;85</td>
###xml 711 724 709 722 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>n</italic>&#160;=&#160;224</td><td align="left"><italic>n</italic>&#160;=&#160;85</td></tr>
###xml 724 732 722 730 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Genotype</td>
###xml 732 733 730 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 732 737 730 735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic> (%)</td>
###xml 737 738 735 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 737 742 735 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic> (%)</td>
###xml 742 742 740 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 742 742 740 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 724 742 722 740 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left"/><td align="left"/></tr>
###xml 742 744 740 742 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ll</td>
###xml 744 753 742 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78 (34.8)</td>
###xml 753 762 751 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26 (30.6)</td>
###xml 762 762 760 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 762 762 760 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 742 762 740 760 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ll</td><td align="left">78 (34.8)</td><td align="left">26 (30.6)</td><td align="left"/><td align="left"/></tr>
###xml 762 764 760 762 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ls</td>
###xml 764 774 762 772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">107 (47.8)</td>
###xml 774 783 772 781 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">37 (43.5)</td>
###xml 783 799 781 797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.28 (0.89&#8211;1.84)</td>
###xml 799 799 797 797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 762 799 760 797 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ls</td><td align="left">107 (47.8)</td><td align="left">37 (43.5)</td><td align="left">1.28 (0.89&#8211;1.84)</td><td align="left"/></tr>
###xml 799 801 797 799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ss</td>
###xml 801 810 799 808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">39 (17.4)</td>
###xml 810 819 808 817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22 (25.9)</td>
###xml 819 835 817 833 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.63 (0.79&#8211;3.39)</td>
###xml 835 840 833 838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.184</td>
###xml 799 840 797 838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ss</td><td align="left">39 (17.4)</td><td align="left">22 (25.9)</td><td align="left">1.63 (0.79&#8211;3.39)</td><td align="left">0.184</td></tr>
###xml 552 840 550 838 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left">OR</td><td align="left"><italic>p</italic><sup><italic>a</italic></sup></td></tr><tr><td align="left">ll</td><td align="left">104 (33.7)</td><td align="left">108 (34.3)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ls</td><td align="left">144 (46.6)</td><td align="left">155 (49.2)</td><td align="left">1.08 (0.86&#8211;1.36)</td><td align="left"/></tr><tr><td align="left">ss</td><td align="left">61 (19.7)</td><td align="left">52 (16.5)</td><td align="left">1.17 (0.74&#8211;1.85)</td><td align="left">0.496</td></tr><tr><td align="left" rowspan="2"/><td align="left">Type 1 psoriasis <sup>b</sup></td><td align="left">Type 2 psoriasis <sup>c</sup></td><td align="left" rowspan="2"/><td align="left" rowspan="2"/></tr><tr><td align="left"><italic>n</italic>&#160;=&#160;224</td><td align="left"><italic>n</italic>&#160;=&#160;85</td></tr><tr><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ll</td><td align="left">78 (34.8)</td><td align="left">26 (30.6)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ls</td><td align="left">107 (47.8)</td><td align="left">37 (43.5)</td><td align="left">1.28 (0.89&#8211;1.84)</td><td align="left"/></tr><tr><td align="left">ss</td><td align="left">39 (17.4)</td><td align="left">22 (25.9)</td><td align="left">1.63 (0.79&#8211;3.39)</td><td align="left">0.184</td></tr></tbody>
###xml 507 840 505 838 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left">Psoriasis patients</th><th align="left">Control group</th><th align="left" rowspan="2"/><th align="left" rowspan="2"/></tr><tr><th align="left"><italic>n</italic>&#160;=&#160;309</th><th align="left"><italic>n</italic>&#160;=&#160;315</th></tr></thead><tbody><tr><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left">OR</td><td align="left"><italic>p</italic><sup><italic>a</italic></sup></td></tr><tr><td align="left">ll</td><td align="left">104 (33.7)</td><td align="left">108 (34.3)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ls</td><td align="left">144 (46.6)</td><td align="left">155 (49.2)</td><td align="left">1.08 (0.86&#8211;1.36)</td><td align="left"/></tr><tr><td align="left">ss</td><td align="left">61 (19.7)</td><td align="left">52 (16.5)</td><td align="left">1.17 (0.74&#8211;1.85)</td><td align="left">0.496</td></tr><tr><td align="left" rowspan="2"/><td align="left">Type 1 psoriasis <sup>b</sup></td><td align="left">Type 2 psoriasis <sup>c</sup></td><td align="left" rowspan="2"/><td align="left" rowspan="2"/></tr><tr><td align="left"><italic>n</italic>&#160;=&#160;224</td><td align="left"><italic>n</italic>&#160;=&#160;85</td></tr><tr><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ll</td><td align="left">78 (34.8)</td><td align="left">26 (30.6)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ls</td><td align="left">107 (47.8)</td><td align="left">37 (43.5)</td><td align="left">1.28 (0.89&#8211;1.84)</td><td align="left"/></tr><tr><td align="left">ss</td><td align="left">39 (17.4)</td><td align="left">22 (25.9)</td><td align="left">1.63 (0.79&#8211;3.39)</td><td align="left">0.184</td></tr></tbody></table>
###xml 840 841 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 857 858 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 840 892 838 890 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24"><sup>a</sup>Two-sided exact <italic>p</italic> from Cochrane-Armitage trend-test</p>
###xml 892 893 890 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 892 933 890 931 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><sup>b</sup>Type 1 psoriasis: age at onset &lt;40&#160;years</p>
###xml 933 934 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 933 976 931 972 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><sup>c</sup>Type 2 psoriasis: age at onset &#8805;40&#160;years</p>
###xml 840 976 838 972 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24"><sup>a</sup>Two-sided exact <italic>p</italic> from Cochrane-Armitage trend-test</p><p textid="25"><sup>b</sup>Type 1 psoriasis: age at onset &lt;40&#160;years</p><p textid="26"><sup>c</sup>Type 2 psoriasis: age at onset &#8805;40&#160;years</p></table-wrap-foot>
###xml 470 976 468 972 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="23">5-HTTLPR genotype distribution</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left">Psoriasis patients</th><th align="left">Control group</th><th align="left" rowspan="2"/><th align="left" rowspan="2"/></tr><tr><th align="left"><italic>n</italic>&#160;=&#160;309</th><th align="left"><italic>n</italic>&#160;=&#160;315</th></tr></thead><tbody><tr><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left">OR</td><td align="left"><italic>p</italic><sup><italic>a</italic></sup></td></tr><tr><td align="left">ll</td><td align="left">104 (33.7)</td><td align="left">108 (34.3)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ls</td><td align="left">144 (46.6)</td><td align="left">155 (49.2)</td><td align="left">1.08 (0.86&#8211;1.36)</td><td align="left"/></tr><tr><td align="left">ss</td><td align="left">61 (19.7)</td><td align="left">52 (16.5)</td><td align="left">1.17 (0.74&#8211;1.85)</td><td align="left">0.496</td></tr><tr><td align="left" rowspan="2"/><td align="left">Type 1 psoriasis <sup>b</sup></td><td align="left">Type 2 psoriasis <sup>c</sup></td><td align="left" rowspan="2"/><td align="left" rowspan="2"/></tr><tr><td align="left"><italic>n</italic>&#160;=&#160;224</td><td align="left"><italic>n</italic>&#160;=&#160;85</td></tr><tr><td align="left">Genotype</td><td align="left"><italic>n</italic> (%)</td><td align="left"><italic>n</italic> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ll</td><td align="left">78 (34.8)</td><td align="left">26 (30.6)</td><td align="left"/><td align="left"/></tr><tr><td align="left">ls</td><td align="left">107 (47.8)</td><td align="left">37 (43.5)</td><td align="left">1.28 (0.89&#8211;1.84)</td><td align="left"/></tr><tr><td align="left">ss</td><td align="left">39 (17.4)</td><td align="left">22 (25.9)</td><td align="left">1.63 (0.79&#8211;3.39)</td><td align="left">0.184</td></tr></tbody></table><table-wrap-foot><p textid="24"><sup>a</sup>Two-sided exact <italic>p</italic> from Cochrane-Armitage trend-test</p><p textid="25"><sup>b</sup>Type 1 psoriasis: age at onset &lt;40&#160;years</p><p textid="26"><sup>c</sup>Type 2 psoriasis: age at onset &#8805;40&#160;years</p></table-wrap-foot></table-wrap>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
The absolute and relative genotype frequencies of the 5-HTTLPR polymorphism are given in Table 1. The genotype frequencies in cases and controls were in Hardy-Weinberg equilibrium. The genotype frequencies were similar among patients with psoriasis vulgaris and healthy controls. In addition, there was no difference in genotype frequencies between patients with early onset- (type I; age at onset <40 years) and late onset psoriasis (type II; age at onset >/=40 years).Table 15-HTTLPR genotype distributionPsoriasis patientsControl groupn = 309n = 315Genotypen (%)n (%)ORpall104 (33.7)108 (34.3)ls144 (46.6)155 (49.2)1.08 (0.86-1.36)ss61 (19.7)52 (16.5)1.17 (0.74-1.85)0.496Type 1 psoriasis bType 2 psoriasis cn = 224n = 85Genotypen (%)n (%)ll78 (34.8)26 (30.6)ls107 (47.8)37 (43.5)1.28 (0.89-1.84)ss39 (17.4)22 (25.9)1.63 (0.79-3.39)0.184aTwo-sided exact p from Cochrane-Armitage trend-testbType 1 psoriasis: age at onset <40 yearscType 2 psoriasis: age at onset >/=40 years
###end p 22
###begin p 23
5-HTTLPR genotype distribution
###end p 23
###begin p 24
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 17 18 17 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
aTwo-sided exact p from Cochrane-Armitage trend-test
###end p 24
###begin p 25
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bType 1 psoriasis: age at onset <40 years
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cType 2 psoriasis: age at onset >/=40 years
###end p 26
###begin p 27
###xml 253 254 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
HAM-D was 5.1 +/- 5.3 in psoriasis patients (mean +/- SD), with 20% of patients suffering from an at least mild depression (HAM-D >8). HAM-D was significantly higher in female psoriasis patients compared with male patients (7.2 +/- 5.9 vs. 3.7 +/- 4.5, p = 0.0001).
###end p 27
###begin p 28
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 670 677 670 677 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 677 735 677 735 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">HAM-D in psoriasis patients according to 5-HTTLPR genotype</p>
###xml 677 735 677 735 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">HAM-D in psoriasis patients according to 5-HTTLPR genotype</p></caption>
###xml 735 740 735 740 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">HAM-D</th>
###xml 740 757 740 757 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">5-HTTLPR genotype</th>
###xml 735 757 735 757 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">HAM-D</th><th align="left" colspan="3">5-HTTLPR genotype</th></tr>
###xml 761 762 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 757 768 757 768 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ll (<italic>n</italic>&#160;=&#160;48)</th>
###xml 772 773 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 768 779 768 779 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ls (<italic>n</italic>&#160;=&#160;67)</th>
###xml 783 784 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 779 790 779 790 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ss (<italic>n</italic>&#160;=&#160;22)</th>
###xml 757 790 757 790 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">ll (<italic>n</italic>&#160;=&#160;48)</th><th align="left">ls (<italic>n</italic>&#160;=&#160;67)</th><th align="left">ss (<italic>n</italic>&#160;=&#160;22)</th></tr>
###xml 735 790 735 790 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">HAM-D</th><th align="left" colspan="3">5-HTTLPR genotype</th></tr><tr><th align="left">ll (<italic>n</italic>&#160;=&#160;48)</th><th align="left">ls (<italic>n</italic>&#160;=&#160;67)</th><th align="left">ss (<italic>n</italic>&#160;=&#160;22)</th></tr></thead>
###xml 790 799 790 799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean (SD)</td>
###xml 799 808 799 808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.4 (5.7)</td>
###xml 808 817 808 817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.3 (5.3)</td>
###xml 817 826 817 826 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.7 (5.4)</td>
###xml 790 826 790 826 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean (SD)</td><td align="left">5.4 (5.7)</td><td align="left">5.3 (5.3)</td><td align="left">4.7 (5.4)</td></tr>
###xml 826 840 826 840 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Median (range)</td>
###xml 840 848 840 848 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (0;25)</td>
###xml 848 856 848 856 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (0;21)</td>
###xml 856 864 856 864 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (0;26)</td>
###xml 826 864 826 864 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Median (range)</td><td align="left">4 (0;25)</td><td align="left">4 (0;21)</td><td align="left">4 (0;26)</td></tr>
###xml 864 878 864 878 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">25. percentile</td>
###xml 878 879 878 879 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 879 880 879 880 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 880 881 880 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 864 881 864 881 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">25. percentile</td><td align="left">1</td><td align="left">1</td><td align="left">2</td></tr>
###xml 881 895 881 895 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">75. percentile</td>
###xml 895 896 895 896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8</td>
###xml 896 899 896 899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7.5</td>
###xml 899 900 899 900 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7</td>
###xml 881 900 881 900 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">75. percentile</td><td align="left">8</td><td align="left">7.5</td><td align="left">7</td></tr>
###xml 790 900 790 900 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Mean (SD)</td><td align="left">5.4 (5.7)</td><td align="left">5.3 (5.3)</td><td align="left">4.7 (5.4)</td></tr><tr><td align="left">Median (range)</td><td align="left">4 (0;25)</td><td align="left">4 (0;21)</td><td align="left">4 (0;26)</td></tr><tr><td align="left">25. percentile</td><td align="left">1</td><td align="left">1</td><td align="left">2</td></tr><tr><td align="left">75. percentile</td><td align="left">8</td><td align="left">7.5</td><td align="left">7</td></tr></tbody>
###xml 735 900 735 900 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">HAM-D</th><th align="left" colspan="3">5-HTTLPR genotype</th></tr><tr><th align="left">ll (<italic>n</italic>&#160;=&#160;48)</th><th align="left">ls (<italic>n</italic>&#160;=&#160;67)</th><th align="left">ss (<italic>n</italic>&#160;=&#160;22)</th></tr></thead><tbody><tr><td align="left">Mean (SD)</td><td align="left">5.4 (5.7)</td><td align="left">5.3 (5.3)</td><td align="left">4.7 (5.4)</td></tr><tr><td align="left">Median (range)</td><td align="left">4 (0;25)</td><td align="left">4 (0;21)</td><td align="left">4 (0;26)</td></tr><tr><td align="left">25. percentile</td><td align="left">1</td><td align="left">1</td><td align="left">2</td></tr><tr><td align="left">75. percentile</td><td align="left">8</td><td align="left">7.5</td><td align="left">7</td></tr></tbody></table>
###xml 670 900 670 900 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="29">HAM-D in psoriasis patients according to 5-HTTLPR genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">HAM-D</th><th align="left" colspan="3">5-HTTLPR genotype</th></tr><tr><th align="left">ll (<italic>n</italic>&#160;=&#160;48)</th><th align="left">ls (<italic>n</italic>&#160;=&#160;67)</th><th align="left">ss (<italic>n</italic>&#160;=&#160;22)</th></tr></thead><tbody><tr><td align="left">Mean (SD)</td><td align="left">5.4 (5.7)</td><td align="left">5.3 (5.3)</td><td align="left">4.7 (5.4)</td></tr><tr><td align="left">Median (range)</td><td align="left">4 (0;25)</td><td align="left">4 (0;21)</td><td align="left">4 (0;26)</td></tr><tr><td align="left">25. percentile</td><td align="left">1</td><td align="left">1</td><td align="left">2</td></tr><tr><td align="left">75. percentile</td><td align="left">8</td><td align="left">7.5</td><td align="left">7</td></tr></tbody></table></table-wrap>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
To assess whether allelic variants of 5-HTTLPR polymorphism may be associated with depressive symptoms in psoriatic patients, the HAM-D was compared between patients with psoriasis (n = 137) characterized by carriage of 0, 1 or 2 s alleles, corresponding to the ll, ls and ss genotypes, respectively. Mean and SD as well as median and 25 and 75% percentiles of the HAM-D were similar in these subgroups (Table 2). As there was a significant difference in the HAM-D between male and female patients, HAM-D values were also compared separately in male and female carriers of 5-HTTLPR genotypes. No significant differences were observed in these subgroups (data not shown).Table 2HAM-D in psoriasis patients according to 5-HTTLPR genotypeHAM-D5-HTTLPR genotypell (n = 48)ls (n = 67)ss (n = 22)Mean (SD)5.4 (5.7)5.3 (5.3)4.7 (5.4)Median (range)4 (0;25)4 (0;21)4 (0;26)25. percentile11275. percentile87.57
###end p 28
###begin p 29
###xml 19 27 <span type="species:ncbi:9606">patients</span>
HAM-D in psoriasis patients according to 5-HTTLPR genotype
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
To the best of our knowledge, this is the first study to investigate a possible relationship between a functionally relevant polymorphism in the promoter of the gene encoding the serotonin transporter and an inflammatory skin disorder. The control group showed genotype frequencies of the 5-HTTLPR polymorphism similar to those reported in an earlier study with healthy German individuals [12]. We found no association of the 5-HTTLPR polymorphism with psoriasis vulgaris, and the obtained 95% CIs indicate that major effects are unlikely.
###end p 31
###begin p 32
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 658 660 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 816 818 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
Depressive symptoms have been reported to be more prevalent among psoriatic patients than among healthy individuals [1]. However, it has not been established whether depression is exclusively a consequence of the impaired quality of life and stigmatization of the disease or whether neuroimmunological mechanisms may also contribute to depressive symptoms. The observation of elevated levels of proinflammatory cytokines in depressive patients and the relatively frequent induction of depressive symptoms during the therapeutic application of interferon-alpha point to a possible role of proinflammatory cytokines in the development of depressive disorders [19]. The reduction of depressive symptoms in patients with psoriasis treated with the TNF-antagonist etanercept parallel to the improvement of skin symptoms [23] could, therefore, be interpreted not only as an indirect effect, but also as a direct effect related to the modulation of peripheral or central neurological functions.
###end p 32
###begin p 33
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 535 542 <span type="species:ncbi:9606">patient</span>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
###xml 699 707 <span type="species:ncbi:9606">patients</span>
###xml 774 781 <span type="species:ncbi:9606">patient</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
###xml 1596 1604 <span type="species:ncbi:9606">patients</span>
Both depression and psoriasis are complex diseases. Carriage of the 's' allele of the 5-HTTLPR polymorphism has been shown to influence susceptibility to develop depressive symptoms after stressful life events but also in association with other diseases such as Parkinson's disease [4, 14, 25]. In our study, we could not find a significant difference in the HAM-D among carriers of different 5-HTTLPR genotypes. However, there are significant limitations to this finding. Low overall HAM-D values among patients with psoriasis in our patient sample may indicate an under-representation of patients with more pronounced depressive symptoms. This is possibly related to the fact that the majority of patients was recruited from a specialized outpatient clinic with optimized patient care. From previous studies, it is evident that different factors are likely to confound the presence and severity of depressive symptoms in psoriasis including gender, severity of skin symptoms and impairment of quality of life [21]. In accordance with the earlier results [18], more pronounced depressive symptoms were observed among female compared with male patients in this study, possibly as a result of gender-specific differences in the prevalence of depression and in the impact of skin diseases on overall well being and self-perception. In light of these findings, it is likely that much larger studies are necessary to establish a relationship between depressive symptoms and genetic variations such as the 5-HTTLPR polymorphism in psoriasis, and that the results obtained with a subgroup of psoriatic patients in this study can only be regarded as preliminary.
###end p 33
###begin p 34
###xml 1115 1117 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1453 1455 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 2071 2072 2071 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 1162 1170 <span type="species:ncbi:9606">patients</span>
###xml 1565 1573 <span type="species:ncbi:9606">patients</span>
###xml 1639 1644 <span type="species:ncbi:9606">woman</span>
###xml 2061 2069 <span type="species:ncbi:9606">patients</span>
The serotonin/serotonin transporter system is a possible link between neuropsychological and immunological functions that may particularly be relevant in diseases such as psoriasis that are characterized by stress-induced chronic inflammation and an increased prevalence of depression. In this pilot study, we failed to demonstrate an association between psoriasis and the functionally relevant 5-HTTLPR polymorphisms of the serotonin transporter. There was also no association between depressive symptoms as measured by the HAM-D and carriage of different 5-HTTLRP genotypes in a subgroup of patients with psoriasis. This does not exclude a small contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility or a modulatory effect on the development of depressive symptoms in patients affected by the disease. The specific limitation of the study related to the small number of individuals enrolled is underlined by recent studies indicating that analysis of several thousand individuals may be necessary to detect associations between SNPs of genes involved in psoriasis pathophysiology and the disease [16]. However, smaller studies with hundreds of patients have, for example, been able to identify association between the 5-HTTLPR polymorphism and anxiety-related personality traits in line with the conclusion that the findings from the present investigation at least argue against a major role of the 5-HTTLPR polymorphism in psoriasis [22]. In addition, it may be necessary to analyse genetic influences on depression separately in male and female patients with psoriasis, as depressive symptoms tend to be more severe in woman-as in our study-and genetic effects of the 5-HTTLPR may be superimposed by gender effects. Finally, other functionally relevant genetic variations of the serotonergic system have been identified including a variable number of tandem repeat polymorphism in intron 2 of the 5-HTT gene and polymorphism of serotonin receptors that could play a role in the pathogenesis of psoriasis and depressive symptoms in psoriasis patients [2]. Larger prospective trials are needed to evaluate the genetic basis of the complex interaction of psoriasis, environmental stressors, gender and development of depressive symptoms.
###end p 34
###begin p 35
We thank Melanie Walter and Dajana Meinhardt for excellent technical assistance. This work was supported by a scholarship from the Deutscher Psoriasis Bund to GS and RM.
###end p 35
###begin p 36
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 36
###begin title 37
References
###end title 37
###begin article-title 38
Assessment of depression in subjects with psoriasis vulgaris and lichen planus
###end article-title 38
###begin article-title 39
###xml 22 27 <span type="species:ncbi:9606">human</span>
A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation
###end article-title 39
###begin article-title 40
Getting under the skin: the immunogenetics of psoriasis
###end article-title 40
###begin article-title 41
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
###end article-title 41
###begin article-title 42
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension
###end article-title 42
###begin article-title 43
###xml 21 26 <span type="species:ncbi:9606">human</span>
Allelic variation of human serotonin transporter gene expression
###end article-title 43
###begin article-title 44
###xml 32 37 <span type="species:ncbi:9606">human</span>
The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release
###end article-title 44
###begin article-title 45
5-hydroxytryptamine induces mast cell adhesion and migration
###end article-title 45
###begin article-title 46
Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?
###end article-title 46
###begin article-title 47
Meta-analysis supports association between serotonin transporter (5-HTT) and suicidal behavior
###end article-title 47
###begin article-title 48
A functional serotonin transporter gene polymorphism is associated with migraine with aura
###end article-title 48
###begin article-title 49
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 49
###begin article-title 50
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease
###end article-title 50
###begin article-title 51
Role of serotonin in the immune system and in neuroimmune interactions
###end article-title 51
###begin article-title 52
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis
###end article-title 52
###begin article-title 53
A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T-cells
###end article-title 53
###begin article-title 54
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Prevalence and correlates of suicidal ideation among patients with skin disease
###end article-title 54
###begin article-title 55
Cytokines sing the blues: inflammation and the pathogenesis of depression
###end article-title 55
###begin article-title 56
Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1 beta are associated with different subtypes of psoriasis characterized by early and late disease onset
###end article-title 56
###begin article-title 57
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Role of depression in quality of life for patients with psoriasis
###end article-title 57
###begin article-title 58
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls
###end article-title 58
###begin article-title 59
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
###end article-title 59
###begin article-title 60
Tests for establishing compatibility of an observed genotype distribution with Hardy-Weinberg equilibrium in the case of a biallelic locus
###end article-title 60
###begin article-title 61
Stressful life events, 5-HTT genotype and risk of depression
###end article-title 61

